{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:31:31Z","timestamp":1790346691001,"version":"4.1.0"},"reference-count":27,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"NIH","award":["P30 DK063720"],"award-info":[{"award-number":["P30 DK063720"]}]},{"name":"NIH","award":["R35CA253175"],"award-info":[{"award-number":["R35CA253175"]}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,3,17]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint blockade (ICB) can induce antitumor efficacy but also induces immune-related adverse events. Systemically administered ICB can activate immune cells throughout the host. Conditionally active ICB with proteolytically cleaved masking domains can potentially reduce the adverse events seen with anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antibody.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We examined how different formats of a conditionally activated dual variable domain IgG (DVD) that binds CTLA-4 and the tumor-associated antigen prostate stem cell antigen (PSCA) can lead to efficacy in syngeneic subcutaneous and metastatic murine tumor models. We also defined the capacity of these DVDs to modulate immune responses by multiparameter flow cytometry.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Conditionally active DVDs can uncouple antitumor efficacy from toxicity. A fully cleavable construct (symmetric DVD, sDVD), which can be released from the target tumor cells, showed superior antitumor efficacy compared with asymmetric DVD, which retains its tumor antigen binding. The sDVD elicited the highest tumor-antigen-specific T-cell responses detected in tumors and tumor-draining lymph nodes, as well as presenting the highest rate of intratumoral and splenic \u201cnon-exhausted\u201d antigen-specific CD8 T cells. SDVD also induced the highest degrees of T-cell memory and self-renewal potential. These effects were dependent on PSCA expression by the tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings support the notion that ICB modulation of antitumor immunity away from the tumor cells is critically important for optimal antitumor immunity. The bispecific sDVD antibody design may enable improved systemic antitumor responses than traditional ICB in both primary tumors and metastases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-010566","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T03:14:42Z","timestamp":1743650082000},"page":"e010566","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of tumor localization on antitumor immunity with conditionally activated CTLA-4 blockade"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05519449","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05479812","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06462794","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2270-0676","authenticated-orcid":false,"given":"Marcel","family":"Arias-Badia","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chun Steven","family":"Pai","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee May","family":"Lwin","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiXi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aahir","family":"Srinath","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Musser","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Goodearl","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob V","family":"Gorman","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Ritacco","sequence":"additional","affiliation":[{"name":"AbbVie Bioresearch Center, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Fong","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"},{"name":"Immunology Integrated Research Center, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"2025100313044086000_13.4.e010566.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025100313044086000_13.4.e010566.2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0483"},{"key":"2025100313044086000_13.4.e010566.3","doi-asserted-by":"crossref","unstructured":"Galsky MD , Autio KA , Cabanski CR , et al . Clinical and Translational Results from PORTER, a Multi-cohort Phase 1 Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2025. doi:10.1158\/1078-0432.CCR-24-3693","DOI":"10.1158\/1078-0432.CCR-24-3693"},{"key":"2025100313044086000_13.4.e010566.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq013"},{"key":"2025100313044086000_13.4.e010566.5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002296","article-title":"Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial","volume":"9","author":"Duerinck","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100313044086000_13.4.e010566.6","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines8040670","article-title":"Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial","volume":"8","author":"Schwarze","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"2025100313044086000_13.4.e010566.7","doi-asserted-by":"publisher","DOI":"10.1172\/JCI123391"},{"key":"2025100313044086000_13.4.e010566.8","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature New Biol"},{"key":"2025100313044086000_13.4.e010566.9","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071440","article-title":"Immune-Related Adverse Events Due to Cancer Immunotherapy: Immune Mechanisms and Clinical Manifestations","volume":"16","author":"Casagrande","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025100313044086000_13.4.e010566.10","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001622","article-title":"Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade \u22652 immune-related adverse events in patients with cancer","volume":"8","author":"Allouchery","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100313044086000_13.4.e010566.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1923"},{"key":"2025100313044086000_13.4.e010566.12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI64859"},{"key":"2025100313044086000_13.4.e010566.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0781"},{"key":"2025100313044086000_13.4.e010566.14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay3575","article-title":"Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy","volume":"12","author":"Francis","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025100313044086000_13.4.e010566.15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00262-017-2059-y","article-title":"Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression","volume":"67","author":"Hebb","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2025100313044086000_13.4.e010566.16","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646583"},{"key":"2025100313044086000_13.4.e010566.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805453"},{"key":"2025100313044086000_13.4.e010566.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.12.022"},{"key":"2025100313044086000_13.4.e010566.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.021"},{"key":"2025100313044086000_13.4.e010566.20","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"2025100313044086000_13.4.e010566.21","doi-asserted-by":"crossref","first-page":"113501","DOI":"10.1016\/j.ejca.2023.113501","article-title":"The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?","volume":"198","author":"Di Giacomo","year":"2024","journal-title":"Eur J Cancer"},{"key":"2025100313044086000_13.4.e010566.22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm5663","article-title":"Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4- and PD-1-targeted immunotherapy","volume":"15","author":"Liu","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025100313044086000_13.4.e010566.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1160062"},{"key":"2025100313044086000_13.4.e010566.24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0013"},{"key":"2025100313044086000_13.4.e010566.25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300895120","article-title":"Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies","volume":"120","author":"Lax","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025100313044086000_13.4.e010566.26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20180684"},{"key":"2025100313044086000_13.4.e010566.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-010566","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:04:48Z","timestamp":1759521888000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-010566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,2]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/jitc-2024-010566"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-010566","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}